



## Publicacions

### Càncer cutani no melanoma

1. Hernández S, Toll A, Baselga E, Ribé A, Azua-Romeo J, Pujol RM, Real FX. Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. *J Invest Dermatol* 2007;127:1664-6.
2. Toll A, Real FX. Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?. *Cell Cycle* 2008.;7:2674-81
3. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. *Immunity*. 2008;28:571-80.
4. Toll A, Salgado R, Yébenes M, Martín-Ezquerria G, Gilaberte M, Baró T, Solé F, Alameda F, Espinet B, Pujol RM. MYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. *Br J Dermatol* 2009.;161:1112-8
5. Toll A, Salgado R, Yébenes M, Martín-Ezquerria G, Gilaberte M, Baró T, Solé F, Alameda F, Espinet B, Pujol RM. Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. *Exp Dermatol* 2010;19:151-3
6. Salgado R, Toll A, Alameda F, Baró T, Martín-Ezquerria G, Sanmartín O, Martorell-Calatayud A, Salido M, Almenar S, Solé F, Pujol RM, Espinet B. CKS1B amplification is a frequent event in cutaneous squamous cell carcinoma with aggressive clinical behaviour. *Genes Chromosomes Cancer* 2010;49:1054-61.
7. Hafner C, Toll A, Fernández-Casado A, Earl J, Marquès M, Acquadro F, Méndez-Pertuz M, Urioste M, Malats N, Burns JE, Knowles MA, Cigudosa JC, Hartmann A, Vogt T, Landthaler M, Pujol RM, Real FX. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. *Proc Natl Acad Sci U S A* 2010;107:20780-5.
8. Toll A, Salgado R, Espinet B, Pujol RM. "Eruptive postoperative squamous cell carcinomas" or "hypertrophic lichen planus-like reactions combined with infundibulocystic hyperplasia"? *J Am Acad Dermatol* 2010;63:910-1.
9. Hafner C, Toll A, Real FX. HRAS mutation mosaicism causing urothelial cancer and epidermal nevus. *N Engl J Med* 2011;365:1940-2.
10. Salgado R, Llombart B, M Pujol R, Fernández-Serra A, Sanmartín O, Toll A, Rubio L, Segura S, et al. Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and

fluorescence in situ hybridization methodologies. *Genes Chromosomes Cancer*. 2011;50:510-7.

11. Segura S, Salgado R, Agustí Toll, Gemma Martín-Ezquerro, Mireia Yébenes, Amparo Sáez, Francesc Solé, Carlos Barranco, Pablo Umbert, Blanca Espinet, Ramón Pujol. Identification of (17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays. *Hum Pathol*. 2011;42:176-84.

12. Hafner C, Toll A, Gantner S, Mauerer A, Lurkin I, Acquadro F, Fernández-Casado A, Zwarthoff EC, Dietmaier W, Baselga E, Parera E, Vicente A, Casanova A, Cigudosa J, Mentzel T, Pujol RM, Landthaler M, Real FX. Keratinocytic epidermal nevi are associated with mosaic RAS mutations. *J Med Genet* 2012;49:249-53.

13. Toll A. The Implantation of Mohs Micrographic Surgery in Spain: a Work Still in Progress. *Actas Dermosifiliogr* 2012.;103:759-61.

14. Toll A, Gimeno-Beltrán J, Ferrandiz-Pulido C, Masferrer E, Yébenes M, Jucglà A, Abal L, Martí RM, Sanmartín O, Baró T, Casado B, Gandarillas A, Barranco C, Costa I, Mojal S, García-Patos V, Pujol RM. D2-40 immunohistochemical overexpression in cutaneous squamous cell carcinomas: A marker of metastatic risk. *J Am Acad Dermatol* 2012;67:1310-8.

15. Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M, Langmann T, Singer S, Klingseisen L, Schneider-Brachert W, Toll A, Real FX, Landthaler M, Hafner C. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. *Nat Genet* 2012;44:783-7.

16. Masferrer E, Ferrándiz-Pulido C, Lloveras B, Masferrer-Niubò M, Espinet B, Salido M, Rodríguez-Rivera M, Alemany L, Placer J, Gelabert A, Servitje O, García-Patos V, Pujol RM, Toll A. MYC Copy Number Gains are Associated with Poor Outcome in Penile Squamous Cell Carcinoma. *J Urol* 2012.;188:1965-71.

17. Segura S, Rozas-Muñoz E, Toll A, Martín-Ezquerro G, Masferrer E, Espinet B, Rodríguez M, Baró T, Barranco C, Pujol RM. Evaluation of MYC status in oral lichen planus in patients with progression to oral squamous cell carcinoma. *Br J Dermatol*. 2013;169:106-14. .

18. Ferrándiz-Pulido C, Masferrer E, de Torres I, Lloveras B, Hernandez-Losa J, Mojal S, Salvador C, Morote J, Ramon Y Cajal S, Pujol RM, Garcia-Patos V, Toll A. Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: Correlation with pathologic subtypes, p16(INK4a) expression, and prognosis. *J Am Acad Dermatol* 2013;68:73-82.

19. Toll A, Masferrer E, Hernández-Ruiz ME, Ferrandiz-Pulido C, Yébenes M, Jaka A, Tuneu A, Jucglà A, Gimeno J, Baró T, Casado B, Gandarillas A, Costa I, Mojal S, Peña R, de Herreros AG, García-Patos V, Pujol RM, Hernández-Muñoz I. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases. *J Dermatol Sci*. 2013;72:93-102.

20. Ferrándiz-Pulido C, Hernández-Losa J, Masferrer E, Vivancos A, Somoza R, Marés R, Valverde C, Salvador C, Placer J, Morote J, Pujol RM, Ramon S, Cajal Y, de Torres I, Toll A, García-Patos V. Identification of somatic gene mutations in penile squamous cell carcinoma. *Genes Chromosomes Cancer* 2015.; 54:629-37.
21. Masferrer E, Ferrandiz-Pulido C, Masferrer-Niubó M, Rodríguez-Rodríguez A, Gil I, Pont A, Servitje O, García de Herreros A, Lloveras B, García-Patos V, Pujol RM, Toll A, Hernández-Muñoz I. Epithelial to Mesenchymal Transition in Penile Squamous Cell Carcinoma. *J Urol* 2015 ; 193: 699-705.
22. Toll A, Margalef P, Masferrer E, Ferrandiz-Pulido C, Gimeno J, Pujol RM, Bigas A, Espinosa L. Active nuclear IKK correlates with metastatic risk in cutaneous squamous cell carcinoma. *Arch Dermatol Res* 2015;307:721-9.
23. Toll A, Salgado R, Espinet B, Díaz-Lagares A, Hernández-Ruiz E, Andrades E, Sandoval J, Esteller M, Pujol RM, Hernández-Muñoz I. MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression. *Mol Cancer*.2016;15:53.
24. Toll A, Gimeno J, Baró T, Hernández-Muñoz MI, Pujol RM. Study of Epithelial to Mesenchymal Transition in Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma to Discern an Epithelial Origin 2016. *Am J Dermatopathol*.;38:270-7.

## **Limfoma**

25. Gallardo F, Bellosillo B, Espinet B, Pujol RM, Estrach T, Servitje O, Romagosa V, Barranco C, Boluda S, García M, Solé F, Ariza A, Serrano S. The 'deck chair sign' in specific cutaneous involvement by angioimmunoblastic T cell lymphoma. *Hum Pathol*. 2006;37:867-73.
26. Gallardo F, Pujol RM, Bellosillo B, Ferrer D, García M, Barranco C, Planagumà M, Serrano S. Primary cutaneous B-cell lymphoma (marginal zone) with prominent T-cell component and aberrant dual (T and B) genotype; diagnostic usefulness of laser-capture microdissection. *Br J Dermatol*. 2006;154:162-6.
27. Ferran M, Gallardo F, Baena V, Ferrer A, Florensa L, Pujol RM. The 'deck chair sign' in specific cutaneous involvement by angioimmunoblastic T cell lymphoma. *Dermatology*. 2006; 213:50-2.
28. Gallardo F, Pujol RM, Bellosillo B, Ferrer D, García M, Barranco C, Planagumà M, Serrano S. Primary cutaneous B-cell lymphoma (marginal zone) with prominent T-cell component and aberrant dual (T and B) genotype; diagnostic usefulness of laser-capture microdissection. *Br J Dermatol*. 2006 ;154:162-6.
29. Gallardo F, Bellosillo B, Serrano S, Pujol RM. [Genotypic analysis in primary cutaneous lymphomas using the standardized BIOMED-2 polymerase chain reaction protocols]. *Actas Dermosifiliogr*. 2008;99:608-20.
30. Gallardo F, Pujol RM. Subcutaneous panniculitic-like T-cell lymphoma and other primary cutaneous lymphomas with prominent subcutaneous tissue involvement. *Dermatol Clin*. 2008; 26:529-40

31. Parera E, Toll A, Gallardo F, Bellosillo B, Pujol RM, Martí R. Lichen sclerosus et atrophicus-like lesions in mycosis fungoides. *Br J Dermatol.* 2007;157:411-3.
32. Gallardo F, Pujol RM, Barranco C, Salar A. Progressive painless swelling of glans penis: uncommon clinical manifestation of systemic non-Hodgkin's lymphoma. *Urology.* 2009;73:929.e3-5.
33. Gallardo F, García-Muret MP, Servitje O, Estrach T, Bielsa I, Salar A, Abella E, Barranco C, Pujol RM. Cutaneous lymphomas showing prominent granulomatous component: clinicopathological features in a series of 16 cases. *J Eur Acad Dermatol Venereol.* 2009;23:639-47.
34. Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. *Cancer.* 2009;115:5210-7
35. Gimeno E, Gimenez MT, Alvarez-Larrán A, Gallardo F, Ferrer A, Bellosillo B, Besses C, Salar A. Central nervous system involvement from primary cutaneous large B-cell lymphoma of the leg. *Leuk Res.* 2009;33:e59-60.
36. Muniesa C, Estrach T, Pujol RM, Gallardo F, Garcia-Muret P, Climent J, Servitje O. Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. *J Am Acad Dermatol.* 2010;62:418-26.
37. Salgado R, Servitje O, Gallardo F, Vermeer MH, Ortiz-Romero PL, Karpova MB, Zipser MC, Muniesa C, García-Muret MP, Estrach T, Salido M, Sánchez-Schmidt J, Herrera M, Romagosa V, Suela J, Ferreira BI, Cigudosa JC, Barranco C, Serrano S, Dummer R, Tensen CP, Solé F, Pujol RM, Espinet B. Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. *J Invest Dermatol.* 2010;130:1126-35.
38. Salgado R, Gallardo F, Servitje O, Estrach T, García-Muret MP, Romagosa V, Florensa L, Serrano S, Salido M, Solé F, Pujol RM, Espinet B. Absence of TCR loci chromosomal translocations in cutaneous T-cell lymphomas. *Cancer Genet.* 2011;204:405-9.
39. Espinet B, García-Herrera A, Gallardo F, Baró C, Salgado R, Servitje O, Estrach T, Colomo L, Romagosa V, Barranco C, Serrano S, Campo E, Pujol RM, Solé F. FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type. *Histol Histopathol.* 2011;26:213-21.
40. Sánchez-Schmidt JM, Salgado R, Servitje O, Gallardo F, Ortiz-Romero PL, Karpova MB, Zipser MC, García-Muret MP, Estrach T, Rodríguez-Pinilla SM, Climent F, Suela J, Ferreira BI, Cigudosa JC, Salido M, Barranco C, Serrano S, Dummer R, Solé F, Pujol RM, Espinet B. Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach. *J Invest Dermatol.* 2011;131:269-71.
41. Muniesa C, Pujol RM, Estrach MT, Gallardo F, García-Muret MP, Climent J, Salar A, Servitje O. Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical

clinicopathological and immunophenotypical features. *J Am Acad Dermatol*. 2012;66:650-4

42. López Aventín D, García M, Pedro C, Pujol RM, Gallardo F. Miliary and agminated papules as clinical presentation of a secondary cutaneous follicular lymphoma. *J Am Acad Dermatol*. 2012;67:e195-6.

43. López Aventín D, Gallardo F, Gil I, Martín-Ezquerro G, García M, Bellosillo B, Juanpere N, Pujol RM. Cutis laxa-like mycosis fungoides. *J Dermatol*. 2012;39:548-51.

44. Peñate Y, Hernández-Machín B, Pérez-Méndez LI, Santiago F, Rosales B, Servitje O, Estrach T, Fernández-Guarino M, Calzado L, Acebo E, Gallardo F, Salar A, Izu R, Ortiz-Romero PL, Pujol RM, Fernández-de-Misa R. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. *Br J Dermatol*. 2012;167:174-9.

45. Prasad A, Rabionet R, Espinet B, Zapata L, Puiggros A, Melero C, Puig A, Sarria-Trujillo Y, Ossowski S, Garcia-Muret MP, Estrach T, Servitje O, Lopez-Lerma I, Gallardo F, Pujol RM, Estivill X. Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome. *J Invest Dermatol*. 2016;136:1490-9.

46. López Aventín D, Gallardo F, Sanchez-Gonzalez B, Pujol RM, Salar A. Metronomic chemotherapy for advanced and refractory cutaneous T-cell lymphoma treatment. *J Eur Acad Dermatol Venereol*. 2016;30:136-8

47. Prasad A, Rabionet R, Espinet B, Zapata L, Puiggros A, Melero C, Puig A, Sarria-Trujillo Y, Ossowski S, Garcia-Muret MP, Estrach T, Servitje O, Lopez-Lerma I, Gallardo F, Pujol RM, Estivill X. Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome. *J Invest Dermatol*. 2016;136:1490-9.

48. Gallardo F, Sandoval J, Díaz-Lagares A, Garcia R, D'Altri T, González J, Alegre V, Servitje O, Crujeiras AB, Stefánsson ÓA, Espinet B, Hernández MI, Bellosillo B, Esteller M, Pujol RM, Bigas A, Espinosa L. Notch1 Pathway Activation Results from the Epigenetic Abrogation of Notch-Related MicroRNAs in Mycosis Fungoides. *J Invest Dermatol*. 2015;135:3144-52.

49. Sandoval J, Díaz-Lagares A, Salgado R, Servitje O, Climent F, Ortiz-Romero PL, Pérez-Ferriols A, Garcia-Muret MP, Estrach T, Garcia M, Nonell L, Esteller M, Pujol RM, Espinet B, Gallardo F. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma. *J Invest Dermatol*. 2015 Apr;135:1128-37

## **Melanoma i lesions pigmentades**

50. Carrera C, Segura S, Palou J, Puig S, Segura J, Martí RM, Malvehy J. Seborrheic keratosis like melanoma with folliculotropism. *Arch Dermatol*. 2007;143:373-6.

51. Segura S, Pellacani G, Puig S, Longo C, Bassoli S, Guitera P, Palou J, Menzies S, Seidenari S, Malvehy J. In vivo microscopic features of nodular melanomas:

dermoscopy, confocal microscopy and histopathologic correlates. Arch Dermatol 2008;144:1311-20.

52. Pellacani G, Longo C, Malvehy J, Puig S, Carrera C, Segura S, Bassoli S, Seidenari S. In vivo confocal microscopic and histopathologic correlations of dermoscopic features in 202 melanocytic lesions. Arch Dermatol. 2008; 144:1597-608.

53. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;68:4853-61.

54. Segura S, Puig S, Carrera C, Palou J, Malvehy J. Development of a two-step method for the diagnosis of melanoma by reflectance confocal microscopy. J Am Acad Dermatol. 2009;61:216-29.

55. Carrera C, Palou J, Malvehy J, Segura S, Aguilera P, Salerni G, Lovatto L, Puig-Butillé J, Alós L, Puig S. Early stages of melanoma on the limbs of high-risk patients: clinical, dermoscopic, reflectance confocal microscopy and histopathological characterization for improved recognition. Acta Derm Venereol. 2011;91:137-46.

56. Guitera P, Haydu LE, Menzies SW, Scolyer RA, Hong A, Fogarty GB, Gallardo F, Segura S. Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors. Br J Dermatol. 2014;170:1305-12.

57. Gallardo F, Padrón A, García-Carbonell R, Rius C, González-Perez A, Arumí-Uría M, Iglesias M, Nonell L, Bellosillo B, Segura S, Pujol RM, Lopez-Bigas N, Bertran J, Bigas A, Espinosa L. Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significance. Oncotarget. 2015;6:9284-94.

58. Melchior L, Grauslund M, Bellosillo B, Montagut C, Torres E, Moragón E, et al. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Exp Mol Pathol. 2015;99:485-91.

59. Casadevall D, Vidal J, Gallardo F, Zuccarino F, Arumí-Uría M, Dalmases, Bellosillo B, Montagut C. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. J Med Case Rep. 2016;10:158.

60. González-Cao M, ..., Montagut C, et al.; Spanish Melanoma Group. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. Clin Transl Oncol. 2017 Jan 4. doi: 10.1007/s12094-016-1602-1. [Epub ahead of print]

## **Tècniques diagnòstiques del càncer de pell**

61. Argenziano G, Puig S, Zalaudek I (...) Segura S (...) J Malvehy. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. *J Clin Oncol*. 2006; 24:1877-82.
62. Segura S, Puig S, Carrera C, Palou J, Malvehy J. Dendritic cells in pigmented basal cell carcinoma: a relevant finding by reflectance-mode confocal microscopy. *Arch Dermatol*. 2007; 143:883-6.
63. Longo C, Segura S, Cesinaro AM, Bassoli S, Seidenari S, Pellacani G. An atypical Meyerson's naevus: a dermoscopic, confocal microscopic and immunohistochemical description of one case. *J Eur Acad Dermatol Venereol*. 2007; 21:414-6.
64. Segura S, Puig S, Carrera C, Lecha M, Borges V, Malvehy J. Non-invasive management of non-melanoma skin cancer in patients with cancer predisposition genodermatosis: A role for reflectance confocal microscopy and methyl-aminolevulinate photodynamic therapy. *Eur Acad Dermatol Venereol*. 2011;25: 819-27.
65. Segura S. Noninvasive assessment for noninvasive treatments in dermatology. *Br J Dermatol*. 2013;168:3-4.
66. Gómez-Martín I, Pujol RM, Segura S. A classical dermoscopic vascular pattern in an uncommon location. *J Am Acad Dermatol*. 2016; 75:e57-9.
67. Gómez-Martín I, Moreno S, Pujol RM, Segura S. Pigmented fibroepithelioma of Pinkus: A potential dermoscopic simulator of malignant melanoma. *J Dermatol*. 2016 Jun 23. doi: 10.1111/1346-8138.13485.